[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336657-105":59,"doc-detail-336657-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","apol6-predicts-immunotherapy-efficacy-of-bladder-cancer-by-ferroptosis","APOL6 predicts immunotherapy efficacy of bladder cancer by ferroptosis","","Immune checkpoint inhibitors (ICIs) are increasingly used for bladder cancer (BLCA), yet reliable biomarkers for predicting immunotherapy outcomes remain limited. Ferroptosis, an immunogenic form of cell death, has been linked to increased sensitivity to ICIs, but its mechanisms in BLCA are not fully understood. Using TCGA single-sample gene set enrichment analysis and additional cohorts, the study identifies immunologically distinct BLCA subtypes and establishes APOL6 as a biomarker linked to ICI efficacy, ferroptosis induction, and STAT1 regulation. Results show APOL6, via ACSL4, mediates immunotherapy efficacy through ferroptosis and highlights a STAT1/APOL6/GPX4 axis critical for BLCA response.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/apol6-predicts-immunotherapy-efficacy-of-bladder-cancer-by-ferroptosis/336657/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/apol6-predicts-immunotherapy-efficacy-of-bladder-cancer-by-ferroptosis/336657.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are biomarkers for bladder cancer immunotherapy still insufficient?","Question",{"text":112,"@type":113},"Effective biomarkers for predicting immunotherapeutic outcomes in bladder cancer are still insufficient. The study notes that relying on existing indicators such as PD-L1 alone is inadequate because some patients with negative PD-L1 expression still respond to immunotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role does ferroptosis play in immunotherapy response for bladder cancer?",{"text":117,"@type":113},"Ferroptosis is described as an immunogenic form of cell death that can enhance patient sensitivity to immune checkpoint inhibitors (ICIs). The paper investigates how ferroptosis contributes to improving immunotherapy efficacy in BLCA.",{"name":119,"@type":110,"acceptedAnswer":120},"How does APOL6 relate to immunotherapy efficacy and ferroptosis?",{"text":121,"@type":113},"APOL6 is identified as a biomarker predicting ICI efficacy. The results indicate that APOL6 interacts with ACSL4 to mediate immunotherapy efficacy by promoting ferroptosis, and APOL6 is regulated by STAT1, forming a key STAT1/APOL6/GPX4 axis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336657,1790160298,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Fan etal. BMC Cancer (2024) 24:1046  \n[https://doi.org/10.1186/s12885-024-12820-7](https://doi.org/10.1186/s12885-024-12820-7)  \nBMC Cancer  \n RESEARCH Open Access  \nAPOL6 predicts immunotherapy efficacy of bladder cancer by ferroptosis  \nZhiwei Fan1,2,3†, Yiting Liu1,2,4†, Xuehai Wang2†, Yuting Xu1, Ruiyao Huang2, Weijian Shi2, Yi Qu2, Jialing Ruan2, Chu Zhou2, Xinyuan Zhao2* and Lei Liu 1*  \nAbstract  \nBackground Immune checkpoint inhibitors (ICIs) are rapidly evolving in the management of bladder cancer (BLCA) . Nevertheless, effective biomarkers for predicting immunotherapeutic outcomes in BLCA are still insufficient. Ferroptosis, a form of immunogenic cell death, has been found to enhance patient sensitivity to ICIs. However, the underlying mechanisms offerroptosis in promoting immunotherapy efficacy in BLCA remain obscure.  \nMethods Our analysis of The Cancer Genome Atlas (TCGA) mRNA data using single sample Gene Set Enrichment Analysis (ssGSEA) revealed two immunologically distinct subtypes. Based on these subtypes and various other public cohorts, we identified Apolipoprotein L6 (APOL6) as a biomarker predicting the efficacy of ICIs and explored its immunological correlation and predictive value for treatment. Furthermore, the role of APOL6 in promoting ferroptosisand its mechanism in regulating this process were experimentally validated.  \nResults The results indicate that APOL6 has significant immunological relevance and is indicative of immunologically hot tumors in BLCA and many other cancers. APOL6, interacting with acyl-coenzyme A synthetase long-chain family member 4 (ACSL4), mediates immunotherapy efficacy by ferroptosis. Additionally, APOL6 is regulated by signal transducer and activator of transcription 1 (STAT1) .  \nConclusions To conclude, our findings indicate APOL6 has potential as a predictive biomarker for immunotherapy treatment success estimation and reveal the STAT1/APOL6/GPX4 axis as a critical regulatory mechanism in BLCA. Keywords APOL6, Bladder cancer (BLCA), Immunotherapy, Ferroptosis  \n†Zhiwei Fan, Yiting Liu and Xuehai Wang contributed equally to this work.  \n*Correspondence: Xinyuan Zhao [zhaoxinyuan@ntu.edu.cn](zhaoxinyuan@ntu.edu.cn)[ ](zhaoxinyuan@ntu.edu.cn)Lei Liu [liulei19920123@163.com](liulei19920123@163.com)  \n1 Department of Pathology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong 226006, China  \n2 Department of Occupational Medicine and Environmental Toxicology, Nantong Key Laboratory of Environmental Toxicology, School of Public Health, Nantong University, Nantong 226019, China  \n3 Department of Urology and Andrology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China  \n4 Department of Interventional Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China  \nIntroduction  \nBladder cancer (BLCA) is a significant global health concern, ranking as the tenth most common diagnosed cancer, with approximately 83,190 incident cases and 16,840 deaths reported occurring worldwide each year [1]. The standard first-line treatment for BLCAs involves platinum-based chemotherapy, specifically cisplatin or carboplatin. However, only a minority of patients experience long-term benefits from this treatment [2, 3].  \nIn contrast to traditional chemotherapy and radiation therapy, cancer immunotherapy has made significant strides in research and offers a novel approach to treating malignant tumors [4]. This therapy enhances the patient’s immune response to attack cancer cells, primarily through targeting tumor cell immune evasion  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to ","cbCaihWZrFZfsWXd","https://ap.wps.com/l/cbCaihWZrFZfsWXd","pdf",8024389,18,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"Why are biomarkers for bladder cancer immunotherapy still insufficient?\",\"answer\":\"Effective biomarkers for predicting immunotherapeutic outcomes in bladder cancer are still insufficient. The study notes that relying on existing indicators such as PD-L1 alone is inadequate because some patients with negative PD-L1 expression still respond to immunotherapy.\"},{\"question\":\"What role does ferroptosis play in immunotherapy response for bladder cancer?\",\"answer\":\"Ferroptosis is described as an immunogenic form of cell death that can enhance patient sensitivity to immune checkpoint inhibitors (ICIs). The paper investigates how ferroptosis contributes to improving immunotherapy efficacy in BLCA.\"},{\"question\":\"How does APOL6 relate to immunotherapy efficacy and ferroptosis?\",\"answer\":\"APOL6 is identified as a biomarker predicting ICI efficacy. The results indicate that APOL6 interacts with ACSL4 to mediate immunotherapy efficacy by promoting ferroptosis, and APOL6 is regulated by STAT1, forming a key STAT1/APOL6/GPX4 axis.\"}]","APOL6 predicts immunotherapy efficacy of bladder cancer by ferroptosis | PDF",1790016071,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/81e4e06f6b449c6bdc07badce1edc196.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1003a0dbbbf5898eefb739741e21aa29.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4070c1084570f710e0df882c46373bb4.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/946b302d7e6cc28a34b32118abf27999.webp",980,1301]